Promising HER2+/HR– breast cancer survival with de-escalated therapyJune 15, 2021Breast CancerOncology
CONCERT: Better QoL but not survival with cabazitaxel in metastatic HER2– breast cancerJune 7, 2021Breast Cancer
Genomic signature predicts safety of omitting RT in early breast cancerJune 7, 2021Breast CancerOncology
ACE inhibitor prevents trastuzumab-associated LVEF decline after anthracyclines in BC treatmentJune 7, 2021Breast CancerPreventive Care
Pregnancy effect on chemotherapy does not affect maternal breast cancer outcomesJune 7, 2021Breast CancerOncologyWomen's Health
Trastuzumab deruxtecan-related lung disease in MBC patients can occur anytime in first yearJune 2, 2021Breast CancerPulmonology
Endocrine therapy benefits in premenopausal breast cancer differ by molecular riskMay 26, 2021Breast Cancer
New targeted treatments are major advances for HER2-positive breast cancerMay 21, 2021Breast CancerWomen's HealthOncology
GELATO trial: Chemoimmunotherapy may help in metastatic invasive lobular breast cancerMay 19, 2021Breast Cancer
